developed as a similar biological medicinal product to Neupogen; approved in EU in 9/08; sBLA submitted 12/09 and accepted 2/10
Brand Neutroval Generic XM02
Company name Teva Product type Speciality
Therapeutic category Hematologic agents Key uses severe neutropenia, febrile neutropenia
Other Uses N/A Drug Class granulocyte colony-stimulating factor (G-CSF)
Dosage From SC Expected Approval 2010-Q3
FDA Filing 12/09 Last Update date February 18,2010
Link to news article
Link to press releases